- Home
- AMGN vs PLTR Comparison
AMGN vs PLTR Comparison
Compare AMGN & PLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- PLTR
- Stock Information
- Founded
- AMGN 1980
- PLTR 2003
- Country
- AMGN United States
- PLTR United States
- Employees
- AMGN N/A
- PLTR N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- PLTR Retail: Computer Software & Peripheral Equipment
- Sector
- AMGN Health Care
- PLTR Technology
- Exchange
- AMGN Nasdaq
- PLTR Nasdaq
- Market Cap
- AMGN 156.2B
- PLTR 179.1B
- IPO Year
- AMGN N/A
- PLTR 2020
- Fundamental
- Price
- AMGN $306.95
- PLTR $85.85
- Analyst Decision
- AMGN Buy
- PLTR Hold
- Analyst Count
- AMGN 21
- PLTR 21
- Target Price
- AMGN $323.26
- PLTR $79.06
- AVG Volume (30 Days)
- AMGN 3.0M
- PLTR 104.7M
- Earning Date
- AMGN 05-01-2025
- PLTR 05-05-2025
- Dividend Yield
- AMGN 3.10%
- PLTR N/A
- EPS Growth
- AMGN N/A
- PLTR 111.11
- EPS
- AMGN 7.56
- PLTR 0.19
- Revenue
- AMGN $33,424,000,000.00
- PLTR $2,865,507,000.00
- Revenue This Year
- AMGN $7.36
- PLTR $34.81
- Revenue Next Year
- AMGN $2.18
- PLTR $27.91
- P/E Ratio
- AMGN $40.60
- PLTR $451.58
- Revenue Growth
- AMGN 18.57
- PLTR 28.79
- 52 Week Low
- AMGN $253.30
- PLTR $20.33
- 52 Week High
- AMGN $346.85
- PLTR $125.41
- Technical
- Relative Strength Index (RSI)
- AMGN 47.38
- PLTR 46.51
- Support Level
- AMGN $304.29
- PLTR $84.46
- Resistance Level
- AMGN $317.58
- PLTR $98.17
- Average True Range (ATR)
- AMGN 5.64
- PLTR 4.96
- MACD
- AMGN -2.39
- PLTR 0.65
- Stochastic Oscillator
- AMGN 13.44
- PLTR 45.58
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About PLTR Palantir Technologies Inc.
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.